Type 2 Diabetes Archive

Assessment of Low-Dose Aspirin As Chemoprevention in Type 2 Diabetes

Assessment of Low-Dose Aspirin As Chemoprevention in Type 2 Diabetes

Investigators examined the efficacy of low-dose aspirin in cancer chemoprevention in patients with diabetes.

Diabetes Risk Associated With Cirrhosis, Not Chronic HCV Infection, in HIV+ Patients

Diabetes Risk Associated With Cirrhosis, Not Chronic HCV Infection, in HIV+ Patients

Cirrhosis is associated with an increased risk for diabetes mellitus among patients living with HIV.

Dulaglutide Effective for Patients With T2D, Moderate to Severe CKD

Dulaglutide Effective for Patients With T2D, Moderate to Severe CKD

Glycemic control with once-weekly dulaglutide was similar to that with insulin glargine in patients with type 2 diabetes and moderate to severe chronic kidney disease.

Risk for Type 2 Diabetes May Be Increased With Comorbid Depression, Anxiety

Risk for Type 2 Diabetes May Be Increased With Comorbid Depression, Anxiety

Investigators examined the association between risk for T2D and comorbid depressive and anxiety symptoms.

Cardiovascular Disease Risk Lower in Women With Type 2 Diabetes

Cardiovascular Disease Risk Lower in Women With Type 2 Diabetes

Investigators examined gender differences in baseline characteristics and outcomes in patients with t2d and ASCVD.

Insulin Glargine 300 Safe, Effective in Seniors With T2DM

Insulin Glargine 300 Safe, Effective in Seniors With T2DM

Glargine 300 is associated with significantly lower annualized rates of documented symptomatic hypoglycemia than Gla-100.

Diabetes Treatments

Antidiabetic agents for the treatment of diabetes including maintenance and max doses.

Intensifying Treatment Does Not Negatively Affect Type 2 Diabetes

Intensifying Treatment Does Not Negatively Affect Type 2 Diabetes

Investigators assessed whether intensification of type 2 diabetes therapy affects health status and quality of life.

Thyroid Hormone Decreases Intrahepatic Lipid Content in Type 2 Diabetes

Thyroid Hormone Decreases Intrahepatic Lipid Content in Type 2 Diabetes

The role of low-dose levothyroxine to increase β-oxidation of fatty acids and decreases intrahepatic lipids in patients with type 2 diabetes was examined.

IDegLira: A Cost-Effective Alternative to Basal-Bolus Therapy in T2D

IDegLira: A Cost-Effective Alternative to Basal-Bolus Therapy in T2D

IDegLira is a cost-effective alternative to basal bolus insulin therapy with insulin glargine U100 plus insulin aspart.

ADA: T1D, T2D, GDM Before 26 Weeks Tied to Higher ASD Risk

ADA: T1D, T2D, GDM Before 26 Weeks Tied to Higher ASD Risk

Study shows increased risks of autism spectrum disorder in association with types 1, 2, gestational diabetes.

CAPPRI Scale is Feasible for Assessing Health-Related Quality of Life in Diabetic Distal Sensorimotor Polyneuropathy

CAPPRI Scale is Feasible for Assessing Health-Related Quality of Life in Diabetic Distal Sensorimotor Polyneuropathy

Investigators evaluated the performance of the CAPPRI in assessing health-related quality-of-life outcomes in patients with diabetic distal sensorimotor polyneuropathy.

Risk for Lactic Acidosis in Type 2 Diabetes Associated With Metformin Use

Risk for Lactic Acidosis in Type 2 Diabetes Associated With Metformin Use

Metformin use in patients with chronic kidney disease and the risk for lactic acidosis was examined.

Greater Deficits in Cognitive Function Examined in Diabetes

Greater Deficits in Cognitive Function Examined in Diabetes

Pen vs Patch Bolus Insulin Delivery for T2D Using CGM

Pen vs Patch Bolus Insulin Delivery for T2D Using CGM

Investigators compared 2 methods of delivering bolus insulin, pen vs patch, using metrics from continuous glucose monitoring.

Empagliflozin, Liraglutide Reduce Cardiovascular Mortality Risk

Empagliflozin, Liraglutide Reduce Cardiovascular Mortality Risk

Investigators conducted a meta-analysis to compare the efficacy of SGLT2i, DPP-4i, and GLP-1 agonists for reducing cardiovascular outcomes.

Type 2 Diabetes Does Not Affect Pneumonia Incidence, Outcomes After Stroke

Type 2 Diabetes Does Not Affect Pneumonia Incidence, Outcomes After Stroke

Investigators examined the incidence and outcomes of pneumonia in patients with acute ischemic stroke and type 2 diabetes.

Risk for Below Knee Amputations With Canagliflozin vs Other Antihyperglycemic Agents

Risk for Below Knee Amputations With Canagliflozin vs Other Antihyperglycemic Agents

Investigators analyzed real world data to examine the risk for below-knee amputations in patients with type 2 diabetes taking canagliflozin vs other medications.

ITCA 650 Shows Efficacy in Reducing Weight, HbA1c in Type 2 Diabetes

ITCA 650 Shows Efficacy in Reducing Weight, HbA1c in Type 2 Diabetes

The ITCA 650, a small titanium osmotic mini-pump, provides a subcutaneous infusion of exenatide over 3 or 6 months.

Exenatide, Basal Insulin Combination Effective for Inpatient Treatment of Diabetes

Exenatide, Basal Insulin Combination Effective for Inpatient Treatment of Diabetes

The safety and efficacy of exenatide alone or in combination with basal insulin in surgery and medicine patients with type 2 diabetes examined.

MEDI0382 Safe, Effective for Normalizing Glucose, Weight Loss in Type 2 Diabetes

MEDI0382 Safe, Effective for Normalizing Glucose, Weight Loss in Type 2 Diabetes

MEDI0382 reduced body weight and normalized fasting and postprandial blood glucose levels in patients with type 2 diabetes.

Liraglutide May Prevent Dementia in Elderly With Type 2 Diabetes

Liraglutide May Prevent Dementia in Elderly With Type 2 Diabetes

Investigators examined the efficacy of liraglutide for the prevention of dementia in elderly patients with type 2 diabetes.

Semaglutide vs Dulaglutide for HbA1c, Body Weight Reduction in T2D

Semaglutide vs Dulaglutide for HbA1c, Body Weight Reduction in T2D

Semaglutide was associated with HbA1c and body weight reductions compared with patients taking dulaglutide.

High-Intensity Statins Do Not Worsen Glucose Homeostasis in Type 2 Diabetes

High-Intensity Statins Do Not Worsen Glucose Homeostasis in Type 2 Diabetes

The effect of high-intensity statins compared with low-intensity statins on glycemic control was examined.

Exenatide Shows Efficacy in Improving Renal Outcomes in T2D

Exenatide Shows Efficacy in Improving Renal Outcomes in T2D

Investigators examined the effect of exenatide on estimated glomerular filtration rate, new macroalbuminuria, and 2 renal composites.

Empagliflozin Reduces Risk for Nephropathy Regardless of Blood Pressure, LDL Cholesterol, HbA1c

Empagliflozin Reduces Risk for Nephropathy Regardless of Blood Pressure, LDL Cholesterol, HbA1c

Investigators examined renal outcomes when controlling cardiovascular risk factors, such as blood pressure, LDL-C, and HbA1c.

Chronic Kidney Disease More Common in Type 2 Diabetes Than in Type 1 Diabetes

Chronic Kidney Disease More Common in Type 2 Diabetes Than in Type 1 Diabetes

Investigators examined the prevalence of chronic kidney disease in adults with type 1 diabetes compared with type 2 diabetes.

Study suggests that diabetes can be accurately diagnosed from a single blood sample

Single blood sample looking at fasting glucose and HbA1c was a key predictor of subsequent diagnosis of diabetes.

Dulaglutide Assessed in T2D Patients With Chronic Kidney Disease

Dulaglutide Assessed in T2D Patients With Chronic Kidney Disease

In AWARD-7, eligible patients (N=577) were randomized to receive dulaglutide 1.5mg once-weekly (N=193), dulaglutide 0.75mg (N=190) once-weekly, or insulin glargine daily (N=194), all in combination with insulin lispro, for 52 weeks. HbA1c at 26 weeks with a 0.4% non-inferiority margin was designated as the primary outcome, while secondary outcomes included eGFR and urine albumin-to-creatinine ratio.

Information-Motivation-Behavioral Skills Model Identifies Barriers to Diabetes Medication Adherence

Information-Motivation-Behavioral Skills Model Identifies Barriers to Diabetes Medication Adherence

Investigators used the Information-Motivation-Behavioral skills model of adherence to examine associations between patient characteristics and barriers to adherence to treatment for type 2 diabetes.

Increased Risk for Parkinson Disease in Individuals With Type 2 Diabetes

Increased Risk for Parkinson Disease in Individuals With Type 2 Diabetes

A retrospective cohort study was conducted to determine whether individuals with preexisting type 2 diabetes are at increased risk of developing Parkinson disease.

Associated Outcomes for Metformin-Based Diabetes Treatment After Kidney Transplant

Associated Outcomes for Metformin-Based Diabetes Treatment After Kidney Transplant

Outcomes associated with metformin use for diabetes in patients requiring kidney transplantation were assessed in an observational study linking Scientific Registry of Transplant Recipient data with US pharmacy claims data.

Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes

Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes

Investigators examined the safety and efficacy of empagliflozin 10mg and linagliptin 5 mg in patients uncontrolled on linagliptin.

HbA1c Targets Should Be Personalized in Type 2 Diabetes

HbA1c Targets Should Be Personalized in Type 2 Diabetes

In most patients with type 2 diabetes, the target should be an HbA1c level between 7 and 8 percent.

LV Strain, Hypertrophy Predict Heart Failure in Asymptomatic T2D

LV Strain, Hypertrophy Predict Heart Failure in Asymptomatic T2D

Impaired global longitudinal strain and left ventricular hypertrophy may be predictive of incident heart failure in patients with asymptomatic type 2 diabetes.

Diabetes Medication Reconciliation May Reduce Risk of ED Visits

Diabetes Medication Reconciliation May Reduce Risk of ED Visits

The correlation between the fraction of outpatient diabetes medications reconciled over a six-month period and the composite primary outcome over the subsequent six months was assessed.

SGLT2 Inhibitor Use Linked to Lower Risk for Heart Failure, Death in Type 2 Diabetes

SGLT2 Inhibitor Use Linked to Lower Risk for Heart Failure, Death in Type 2 Diabetes

Regardless of presence of preexisting cardiovascular disease, SGLT2 inhibitors were associated with lower risk for death and heart failure.

Fenofibrate Improves Cholesterol Levels in Type 2 Diabetes

Fenofibrate Improves Cholesterol Levels in Type 2 Diabetes

To understand the mechanism underlying the benefit of fenofibrate on vascular complications in patients with type 2 diabetes, investigators assessed carotid intima thickness as a marker of subclinical atherosclerosis.

Does Metformin Use Increase the Risk for Lactic Acidosis in T2D Patients?

Does Metformin Use Increase the Risk for Lactic Acidosis in T2D Patients?

Results demonstrated an incidence rate of 391/100,000 person years was calculated based on the 163 patients who were hospitalized with lactic acidosis during the follow-up period.

Diabetes Exposure in Utero and Risk of Developing T2D in Offspring

Diabetes Exposure in Utero and Risk of Developing T2D in Offspring

This study demonstrated the importance of early screening and diagnosis of type 2 diabetes in mothers and their offspring.

Safety of DPP-IV Inhibitor, Cardiovascular Events After ACS in Type 2 Diabetes

Safety of DPP-IV Inhibitor, Cardiovascular Events After ACS in Type 2 Diabetes

Investigators examined the time to first event composing of cardiovascular death, myocardial infarction, or stroke.

Abnormal Glucose Regulation Associated With Cognitive Dysfunction in HIV+ Men

Abnormal Glucose Regulation Associated With Cognitive Dysfunction in HIV+ Men

A study sought to determine the relationship between glycemic status and cognition in people living with HIV.

Predictors of Success for Insulin-to-Liraglutide Switch for Type 2 Diabetes

Predictors of Success for Insulin-to-Liraglutide Switch for Type 2 Diabetes

Investigators examined predictors of success of switching from insulin to liraglutide in patients with type 2 diabetes.

MK-1293 Insulin Glargine is a Safe and Effective Treatment Option for Type 2 Diabetes

MK-1293 Insulin Glargine is a Safe and Effective Treatment Option for Type 2 Diabetes

Investigators sought to determine the safety and efficacy of MK-1293 insulin glargine and Lantus in type 2 diabetes.

Contribution of Low-Severity Gestational Diabetes Mellitus on the Diabetes Epidemic

Contribution of Low-Severity Gestational Diabetes Mellitus on the Diabetes Epidemic

Greater awareness of clinical and cost implications of gaps for patients with lower-severity gestational diabetes may improve postdelivery testing and referral.

Semaglutide May Induce Weight Loss in Type 2 Diabetes Despite BMI

Semaglutide May Induce Weight Loss in Type 2 Diabetes Despite BMI

Researchers assessed whether semaglutide-induced weight loss was related to gastrointestinal adverse events.

Composite HbA1c End Point Can Better Gauge Response to Basal Insulin in Type 2 Diabetes

Composite HbA1c End Point Can Better Gauge Response to Basal Insulin in Type 2 Diabetes

Investigators sought to determine baseline and clinical characteristics associated with response to insulin glargine in patients with type 2 diabetes.

Effect of Testosterone Replacement on Glycemic Control in Obese Men With Hypogonadism, T2D

Effect of Testosterone Replacement on Glycemic Control in Obese Men With Hypogonadism, T2D

Investigators examined the effect of testosterone replacement therapy on metabolic syndrome and vascular function in obese males with hypogonadism.

Oral Semaglutide Tops Empagliflozin for HbA1c Improvement: PIONEER 2 Trial

Oral Semaglutide Tops Empagliflozin for HbA1c Improvement: PIONEER 2 Trial

Oral semaglutide 14 mg led to statistically significant improvement in hemoglobin A1c levels and weight loss in adults with type 2 diabetes.

Fewer Major Adverse Cardiovascular Events With New Antihyperglycemic Drugs With Lower Hypoglycemic Risk

Fewer Major Adverse Cardiovascular Events With New Antihyperglycemic Drugs With Lower Hypoglycemic Risk

Investigators proposed that reduction in MACE may be proportional to the magnitude of HbA1c reduction seen with newer antihyperglycemic agents.

Heart Rate Variability in Type 2 Diabetes

Heart Rate Variability in Type 2 Diabetes

Researchers conducted a systemic review and met-analysis to examine the effect of type 2 diabetes on heart rate variability.

Increased Risk for Type 2 Diabetes in Adolescents, Young Adults With ADHD

Increased Risk for Type 2 Diabetes in Adolescents, Young Adults With ADHD

These findings can inform clinical practice in that type 2 diabetes should be considered in ADHD even in the absence of other known risk factors.

Ideal Systolic Blood Pressure for CVD Prevention in Diabetes, Hypertension

Ideal Systolic Blood Pressure for CVD Prevention in Diabetes, Hypertension

Investigators sought to determine whether targeting systolic blood pressure of 140 mmHg in patients with type 2 diabetes would result in adverse CV outcomes.

Inverse Link for Plasma 25(OH)D Concentration, Risk of T2D

Inverse Link for Plasma 25(OH)D Concentration, Risk of T2D

Researchers performed a cohort study involving 903 adults who were known to be free of diabetes or prediabetes during a visit conducted in 1997 to 1999.

Insulin Pen Devices

Insulin Pen Devices comparison chart for patients with diabetes mellitus.

Perioperative Cardiovascular Events More Common in Diabetes

Perioperative Cardiovascular Events More Common in Diabetes

Perioperative major adverse cardiovascular and cerebrovascular events may be more common in patients with diabetes.

Diabetes, HbA1c Independently Associated With Adverse Postoperative Outcomes

Diabetes, HbA1c Independently Associated With Adverse Postoperative Outcomes

Investigators sought to determine an association between diabetes and HbA1C with postoperative outcomes.

Childhood Overweight Increases Risk for Type 2 Diabetes in Adulthood

Childhood Overweight Increases Risk for Type 2 Diabetes in Adulthood

Investigators examined changes in weight from childhood to early adulthood and the risk for developing type 2 diabetes.

Semaglutide Superior to Other GLP-1 Analogues as Add-On to Basal Insulin in T2D

Semaglutide Superior to Other GLP-1 Analogues as Add-On to Basal Insulin in T2D

Overall, once-weekly semaglutide 1.0 mg as an add-on to basal insulin is the most efficacious GLP-1 receptor agonist in terms of reductions in HbA1c and body weight from baseline after 6 months of treatment.

Clinician Perspective: Examining the Link Between Antipsychotics and Diabetes

Clinician Perspective: Examining the Link Between Antipsychotics and Diabetes

Endocrinologist Kevin M. Pantalone, DO, and psychiatrist Christian Kohler, MD, discuss the risk associated with the use of antipsychotic medications in individuals with type 2 diabetes.

ADA Issues White Paper Addressing Escalating Cost of Insulin

ADA Issues White Paper Addressing Escalating Cost of Insulin

There is a lack of transparency throughout the insulin supply chain. It is unclear precisely how the dollars flow and how much each intermediary profits.

Triple-Goal Achievement Reduces Risk for Complications in Type 2 Diabetes

Triple-Goal Achievement Reduces Risk for Complications in Type 2 Diabetes

Treatment strategies targeting hypertension, hyperlipidemia, and hyperglycemia may improve outcomes in patients with type 2 diabetes.

Inverse Association Between Serum 25(OH)D Levels and Risk for Diabetes

Inverse Association Between Serum 25(OH)D Levels and Risk for Diabetes

Further research is needed on whether high 25(OH)D might prevent type 2 diabetes or transition of prediabetes to diabetes.

Use of In-Hospital Continuous Subcutaneous Insulin Infusion: A Consensus Statement

Use of In-Hospital Continuous Subcutaneous Insulin Infusion: A Consensus Statement

To date, published experience with continuous subcutaneous insulin infusion use in the hospital is limited to just a few institutions, and primarily to those instances involving transitioning of the therapy from the outpatient to inpatient setting.

Community Health Worker-Led Intervention Beneficial in T2D

Community Health Worker-Led Intervention Beneficial in T2D

A community health worker-led diabetes self-management education program is associated with sustained improvement in hemoglobin A1c.

Type 2 Diabetes Linked With Higher Risk for Hip Fractures

Type 2 Diabetes Linked With Higher Risk for Hip Fractures

Studies on the antifracture effectiveness of antiosteoporosis medications (or nonpharmacologic treatments) should account for death as a competing risk.

Better Control With DPP-4 Inhibitors vs NPH Insulin in Type 2 Diabetes

Better Control With DPP-4 Inhibitors vs NPH Insulin in Type 2 Diabetes

Patients initiating DPP-4 inhibitors as third-line therapy in type 2 diabetes appeared to have lower discontinuation rates and less hypoglycemia compared with patients starting NPH insulin.

Achieving Glycemic Control in T2D After Basal Insulin Initiation

Achieving Glycemic Control in T2D After Basal Insulin Initiation

Maintaining a basal insulin regimen over 12 or 24 months in a patient who has not yet reached the HbA1c <7% target provides little additional benefit toward reaching this goal.

Lesbian, Bisexual Women More Likely to Develop T2D at Younger Age

Lesbian, Bisexual Women More Likely to Develop T2D at Younger Age

Researchers found that the risk of developing type 2 diabetes was increased for lesbian and bisexual women vs heterosexual women.

Type 2 Diabetes Increases Risk for Renal Cancer in Women, but Not Men

Type 2 Diabetes Increases Risk for Renal Cancer in Women, but Not Men

Type 2 diabetes is independently associated with a greater risk of renal cell carcinoma in women, but not in men.

Novel Signal Identified for Microalbuminuria in Europeans With T2D

Novel Signal Identified for Microalbuminuria in Europeans With T2D

In European T2D cases, the researchers identified a novel signal near GABRR1, which was associated with microalbuminuria.

Reproductive Markers Associated With Risk of Diabetes

Reproductive Markers Associated With Risk of Diabetes

Markers of reproductive history, including age of menarche and parity, may be tied to future diabetes risk in women with a body mass index ≥25.

FDA: REMS No Longer Needed for Inhaled Insulin Afrezza

FDA: REMS No Longer Needed for Inhaled Insulin Afrezza

Upon review of the proposed supplemental New Drug Application (sNDA), the FDA has determined that the communication plan is no longer needed as an element of the REMS to ensure the benefits of Afrezza outweigh its risks.

No Link Between HbA1c Levels and Wound Healing in Patients With Diabetic Foot Ulcers

No Link Between HbA1c Levels and Wound Healing in Patients With Diabetic Foot Ulcers

The paradoxical finding of accelerated wound healing and increase in HbA1c in participants with better baseline glycemic control requires confirmation in further studies.

Insulins

Insulin products chart with pharmacokinetic properties.

Good Glycemic Control May Influence Bone Metabolism in Type 2 Diabetes

Good Glycemic Control May Influence Bone Metabolism in Type 2 Diabetes

Researchers showed that improved glycemic control is associated with higher bone resorption, possibly reflecting normalization rather than an abnormal increase in bone resorption.

Childhood Insulin Resistance Associated With Later Psychosis

Childhood Insulin Resistance Associated With Later Psychosis

The authors advised clinicians to carefully consider which antipsychotics they prescribe their patients with metabolic dysfunction, as some are known to be diabetogenic.

Irregular Menstruation Common in Girls With Type 2 Diabetes

Irregular Menstruation Common in Girls With Type 2 Diabetes

Menstrual dysfunction is common in girls with recently diagnosed type 2 diabetes, and does not improve with 2years of anti-hyperglycemic treatment.

SGLT2 Inhibitors Canagliflozin, Dapagliflozin Compared in Real-World Study

SGLT2 Inhibitors Canagliflozin, Dapagliflozin Compared in Real-World Study

Study compared the real-world effectiveness of canagliflozin 300 mg vs dapagliflozin 10 mg on HbA1c reduction in patients with type 2 diabetes.

Aortic Stiffness, Concentric LV Remodeling Linked in Type 2 Diabetes

Aortic Stiffness, Concentric LV Remodeling Linked in Type 2 Diabetes

Researchers used multiparametric cardiovascular magnetic resonance imaging to examine the correlation between aortic stiffness and LV geometry in younger adults with type 2 diabetes.

Metabolic Syndrome and Skin Disorders: Association Is More Than Skin Deep

Metabolic Syndrome and Skin Disorders: Association Is More Than Skin Deep

Knowing that certain characteristics increase the risk for dermatology patients who may have metabolic syndrome will enable clinicians to identify patients who may have specific cardiovascular risks.

CDC Reports on Diabetes Prevalence by Type in the United States

CDC Reports on Diabetes Prevalence by Type in the United States

The CDC conducted a study to estimate the prevalence of diagnosed diabetes among adults in 2016 by primary type.

Hip Fracture Risk May Be Overestimated in Type 2 Diabetes

Hip Fracture Risk May Be Overestimated in Type 2 Diabetes

Researchers found that estimation of hip fracture risk without accounting for death as a competing event results in an overestimation of fracture risk.

Evening Preference Linked to Higher BMI in Type 2 Diabetes

Evening Preference Linked to Higher BMI in Type 2 Diabetes

Results suggest that circadian preference and meal timing are novel and possibly modifiable risk factors for obesity in type 2 diabetes.

Risk for Fetal Loss Early in Pregnancy Not Greater With Noninsulin vs Insulin Therapy

Risk for Fetal Loss Early in Pregnancy Not Greater With Noninsulin vs Insulin Therapy

Compared to standard insulin treatment, noninsulin antidiabetic agents did not present an increased risk for fetal losses or major malformations when used in the first trimester of pregnancy.

Vitamin D Insufficiency Associated With Insulin Resistance Independent of Obesity in Children

Vitamin D Insufficiency Associated With Insulin Resistance Independent of Obesity in Children

Further clinical trials are needed to explore the potential beneficial effect of vitamin D supplementation, via fortified foods and/or dietary supplements, on insulin resistance, and possibly on weight management.

Factors Identified to Predict Fatty Liver in Obese Teens

Factors Identified to Predict Fatty Liver in Obese Teens

Ethnicity,race, markers of insulin resistance, and genetic factors might help identify obese youth at risk for developing fatty liver.

HbA1c Variability Predicts All-Cause Mortality in Type 2 Diabetes

HbA1c Variability Predicts All-Cause Mortality in Type 2 Diabetes

HbA1c variability is a strong, independent predictor of all-cause mortality in patients with type 2 diabetes and appears to be more powerful than average HbA1c in predicting all-cause death.

Choroidal Thickness Changes in Patients With Untreated Diabetes

Choroidal Thickness Changes in Patients With Untreated Diabetes

Researchers examined the choroidal layer thickness in eyes of patients with diabetes to compare the findings based on medical history of systemic diabetes treatments and stage of diabetic retinopathy.

One-Hour Plasma Glucose Useful Predictor of Diabetic Retinopathy

One-Hour Plasma Glucose Useful Predictor of Diabetic Retinopathy

One-hour plasma glucose is a useful predictor of retinopathy risk, has a predictive value similar to that of 2-hour plasma glucose, and may be considered as an alternative glucose time point during an oral glucose tolerance test.

Social Support of Autonomy Tied to Better Glycemic Control in Diabetes

Social Support of Autonomy Tied to Better Glycemic Control in Diabetes

Family and friends' autonomy support may lead to better glycemic control by reducing distress among patients with diabetes.

SGLT-2 inhibitors and GLP-1 agonists associated with better mortality outcomes than DPP-4 inhibitors for type 2 diabetes

SGLT-2 inhibitors or GLP-1 agonists were associated with lower mortality than DPP-4 inhibitors, placebo, or no treatment. Use of DPP-4 inhibitors was not associated with lower mortality than placebo or no treatment.

Intensive Lifestyle Interventions Cut Long-Term Disability in Type 2 Diabetes

Intensive Lifestyle Interventions Cut Long-Term Disability in Type 2 Diabetes

For overweight or obese adults with T2D, a long-term weight loss intervention is associated with a reduction in long-term disability.

Insulin-Treated Diabetes Reduces Dysglycemia-Related Mortality in Sepsis

Insulin-Treated Diabetes Reduces Dysglycemia-Related Mortality in Sepsis

In patients with insulin-treated diabetes and sepsis, increased highest glucose levels and glycemic variability have a significant illness severity-adjusted association with decreasing in-hospital mortality.

Increased Risk for Mortality in People With Diabetes, CHD Taking Beta-Blockers

Increased Risk for Mortality in People With Diabetes, CHD Taking Beta-Blockers

Further studies are needed to assess whether beta-blockers are effective in reducing mortality and coronary events in patients with diabetes receiving optimal medical treatment.

Oxyntomodulin Augments Glucose Homeostasis

Oxyntomodulin Augments Glucose Homeostasis

In obese subjects with and without type 2 diabetes, oxyntomodulin significantly augments glucose-dependent insulin secretion.

Sacubitril/Valsartan May Help Preserve Kidney Function in Patients With HFrEF

Sacubitril/Valsartan May Help Preserve Kidney Function in Patients With HFrEF

Compared with the enalapril-treated group, those treated with sacubitril/valsartan were found to have significantly slower kidney decline.

Clinicians May Be Overtreating Older Patients With Diabetes

Clinicians May Be Overtreating Older Patients With Diabetes

Future research should further investigate the process and influences on clinician decision-making regarding individualizing glucose targets for high-risk geriatric patients, including the influence of training and practice environment.

No association of overweight childhood and adult type 2 diabetes risk after weight loss

Compared to men who were never overweight, those overweight at age 7 who returned to a normal body mass index by age 13 had no increased risk for developing type 2 diabetes.

Distinct Mechanisms Underlie Nerve Damage in Peripheral Neuropathy in T1D vs T2D

Distinct Mechanisms Underlie Nerve Damage in Peripheral Neuropathy in T1D vs T2D

The type of sciatic nerve lesions observed in patients with diabetic peripheral neuropathy was found to differ in type 1 and type 2 diabetes.

Sign Up for Free e-Newsletters



CME Focus